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Acidosis, not azotemla, stimulates branched-chain, amino acid catab-
olism in uremic rats. To investigate branched-chain, amino acid metab-
olism (BCAA) in muscle in chronic renal failure (CRF), we studied rats
with moderately severe uremia (PUN 110 — mg/dl) and spontaneous
metabolic acidosis (bicarbonate, 19 I mEq/liter). Plasma BCAA
levels in CRF compared to pair—fed control rats were 15% lower and
muscle valine was 93 tM lower (P < 0.05). BCAA metabolism was
measured in incubated epitrochlearis muscles using L-[l-'4C]valine or
L-[l-'4CJleucine in the presence and absence of insulin. BCAA decar-
boxylation was increased (P < 0.05) and insulin-stimulated BCAA
incorporation into protein was blunted (P < 0.05) by CRF. Since we
have found that metabolic acidosis, by itself, stimulates muscle branched-
chain, ketoacid dehydrogenase activity, another group of CRF and
control rats was given NaHCO3 which corrected the acidosis, but not
the azotemia. BCAA decarboxylation in muscle was reduced in CRF
rats given NaHCO3, and this was reflected in increased plasma and
muscle BCAA concentrations. We conclude that in CRF, chronic
metabolic acidosis stimulates BCAA decarboxylation in skeletal muscle
and this could contribute to the reduced intra- and extracellular
concentrations of BCAA. Correction of acidosis should be a goal of
therapy in CRF, especially when dietary regimens restrict intake of
BCAA.
The mechanism accounting for the low plasma levels of
branched—chain amino acids (BCAA), and especially valine, in
patients with chronic renal failure (CRF) is unknown [1].
Possible explanations include inadequate dietary BCAA, mal-
absorption or excessive splanchnic BCAA degradation and/or
increased BCAA catabolism in peripheral tissues. Regarding
dietary deficiency, plasma BCAA concentrations in CRF pa-
tients were found to be subnormal, even when uremic and
control subjects were eating diets identical in protein content
[2]. Malabsorption or increased splanchnic disposal seem un-
likely because BCAA release into hepatic venous blood is
increased in CRF patients compared to normal subjects [3].
These observations suggest that BCAA utilization in peripheral
tissues must be increased by CRF. This hypothesis seems
reasonable since a major portion of BCAA metabolism occurs
extrahepatically [4]. BCAA are first transaminated and then
irreversibly catabolized by the branched-chain, ketoacid dehy-
drogenase complex (BCKAD) [5, 6], the rate-limiting reaction
for BCAA degradation, at least in skeletal muscle [6]. The
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hypothesis also is attractive because metabolic acidosis fre-
quently accompanies CRF and we have found in non-azotemic
rats that chronic metabolic acidosis, by itself, reduces plasma
BCAA levels and increases their oxidative decarboxylation in
muscle. The latter effect measured in vitro reflected stimulation
of BCKAD activity in muscles freeze clamped in vivo [7].
To examine whether CRF changes BCAA metabolism in
muscle, a model of moderately severe uremia was created in
rats, and valine and leucine metabolism were measured. The
model required a high protein diet in order to mimic the level of
azotemia and the mild metabolic acidosis generally present in
CRF patients. The importance of the spontaneous acidosis of
CRF on BCAA metabolism was then evaluated in a second
experiment by supplementing the diet of another group of CRF
rats with sufficient sodium bicarbonate to correct their acidosis.
The results establish that in CRF, metabolic acidosis contrib-
utes to abnormal BCAA metabolism by increasing oxidative
decarboxylation of BCAA in skeletal muscle.
Methods
Ani,nals
Male Sprague-Dawley rats weighing 75 to 100 g (Charles
River Breeding Laboratory, Inc., Wilmington, Masachusetts,
USA) were housed in temperature controlled quarters with a
12-hour lightll2-hour dark cycle, and given water and 14%
protein chow (Agway Country Foods, Syracuse, New York,
USA) ad libitum. After anesthesia with sodium pentobarbitol (5
mg/100 g body wt), approximately 5/6 of the left kidney was
infarcted by ligating branches of the renal artery (CRF). One
week later, a right nephrectomy was performed through a flank
incision. At the same time, the right kidney of weight-matched
control rats (SO) was exposed and manipulated through a flank
incision, but not injured.
CRF and control rats were fed 14% protein for one week and
then switched to a diet that produces normal growth in CRF rats
[8] and pair-fed for 10 days. The diet contained 46% protein and
consisted of casein, RMH 3000 chow (Agway Country Foods)
and dextrin (40:35:25, wt/wt/wt). The food intake of each CRF
rat (approximately 14 g per day) was used to determine the
intake of its paired control rat. CRF and control rats were given
0.0375 M NaCI and water ad libitum, respectively. In another
experiment, rats prepared similarly were pair-fed the diet
supplemented with 1.7% sodium bicarbonate (CRF-HCO3 and
SO-HCO3) to correct the acidosis associated with CRF [9].
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In vivo studies
On the experimental day, rats were anesthetized, the anterior
tibialis and epitrochlearis muscles were removed and aortic
blood was obtained for blood gas analysis, plasma urea nitrogen
(PUN) and BCAA concentrations. To measure BCAA concen-
trations, 100 d of plasma were deproteinized with an equal
volume of 10% perchloric acid (PCA) and then 50 1d of 0.15 M
sodium acetate (pH 4.9) containing fluorophenylalanine as the
internal standard were added. The deproteinized plasma was
neutralized with KOH and reconstituted to a final volume of 0.5
ml before assay. The anterior tibialis muscle was immediately
homogenized in 1.5 ml of ice cold 5% PCA and centrifuged.
Four hundred pi of supernatant were added to 200 1 of the
sodium acetate buffer containing fluorophenylalanine. The mix-
ture was neutralized with KOH, centrifuged and the superna-
tant was reconstituted with sodium acetate buffer to a final
volume of 0.8 ml. Valine, leucine, and isoleucine concentra-
tions in plasma and muscle homogenate samples were measured
as the o-phthaldialdehyde derivatives by a high-performance
liquid chromatography (HPLC) system (Waters Association,
Milford, Massachusets, USA). Intracellular BCAA concentra-
tions in muscle were calculated by subtracting plasma (extra-
cellular) BCAA concentrations, using values for the extracellu-
lar space and water content determined previously [10, 111.
HPLC
Deproteinized, neutralized samples were derivatized with
o-phthaldialdehyde and injected onto a 7.5 cm x 4.6 mm (I.D.)
reverse phase column (Ultrasphere 3 pm, ODS, Beckman
Instruments, Fullerton, California, USA), preceded by a 2.3cm
x 4 mm (ID.) guard column containing 37 to 50 m C18 reverse
phase packing. Mobile phase A consisted of 1% tetrahydrofu-
ran/l9% methyl alcohoII8O% 0.05 M sodium acetate (pH 5.9),
and mobile phase B consisted of 80% methyl alcohol/20% 0.05
M sodium acetate (pH 5.9). The solvent program was: a) linear
gradient to 90% A/l0% B at 1 mllmin over 0.8 minutes; b)
convex gradient to 60% A/40% B at 1 ml/min over 3.2 minutes;
c) linear gradient to 30% A!70% B at 1 mllmin over 16 minutes;
d) 100% B isocratic at 1.3 ml/min over 5 minutes; e) linear
gradient back to the initial solvent composition at 1.3 mllmin
over 2 minutes. Samples were quantitated by comparison with
known amounts of standards and concentrations were calcu-
lated using the internal standard.
In vitro studies
The epitrochlearis muscles were blotted, weighed, and im-
mediately placed in flasks containing 3 ml Krebs-Henseleit
buffer, equilibrated with 95% 02/5% CO2 (pH 7.4). The prein-
cubation media contained 10 m glucose and either 0.2 mM
valine or 0.15 mM leucine. After 30 minutes of preincubation in
a shaking water bath at 37°C, muscles were removed, blotted,
transferred to flasks containing fresh media, with or without 1
mU/ml insulin, and regassed before incubating for a 2-hour
experimental period.
In studies of valine metabolism, L-[l-'4C]valine (0.25 mCi/
mmol) was added to the experimental incubation media which
contained 0.2 mri valine; in studies of leucine metabolism,
L-[l-'4C]leucine (0.33 mCilmmol) was added to media which
contained 0.15 m leucine. At the end of the experimental
period, the flasks were placed on ice and 2 ml of media were
transferred by syringe to another stoppered flask containing 0.5
ml of 50% trichloroacetic acid and a hanging center well with
0.2 ml phenethylamine to collect '4C02. After one hour of
incubation at 37°C, the '4C02 trapped in the center well was
measured by liquid scintillation counting with correction for
quenching using an external standard. The 14C02 collected was
divided by the intracellular specific radioactivity of the amino
acid in order to calculate the rate of amino acid decarboxyla-
tion. This was done because we were unable to measure the
intracellular specific radioactivity of the appropriate cl-ketoacid
reliably, but others have shown that it is in equilibrium with that
of the respective amino acid in rat skeletal muscle [121.
Stoppers with new center wells containing 0.2 ml of fresh
phenethylamine were placed, 0.5 ml of 50% H202 were injected
into the stoppered flasks, and they were incubated for an addi-
tional hour at 37°C to collect 14C02 liberated from decarboxy-
lation of the [1-'4C]a-ketoacid [13]. The net rate of transamina-
tion was calculated as the sum of the rates of decarboxylation of
the amino acid and ketoacid divided by the intracellular specific
radioactivity of the amino acid.
Radioactivity and the concentrations of valine and leucine in
the acid-soluble fraction of the muscle homogenate were deter-
mined and used to calculate the specific radioactivity of the
amino acid in intracellular fluid [7]. In this calculation, values
for total tissue water and extracellular space of the epitrochle-
aris muscle determined previously [11] were used. The total
acid soluble radioactivity was used for this calculation because
earlier experiments [7] showed that the14CO2 evolved by decar-
boxylating the a-ketoacid present in the muscle supernatant
with H202 [13] was less than 5% of the total radioactivity in the
supernatant. Moreover, by analyzing the supernatant and the
media, we found that the estimated intracellular £1-ketoacid was
less than 5% of the total a-ketoacid in both compartments,
Therefore, the net rate of transamination was calculated as the
amount of l-14C-cx-ketoacid present in the media plus the '4C02
formed from the L[1-14C]amino acid during the experimental
incubation divided by the intracellular specific radioactivity of
the amino acid.
In an earlier study, epitrochlearis muscles from control rats
were studied by the same methods. After the 30 minute pre-
incubation, one muscle from each rat was incubated for 60
minutes and the contralateral muscle incubated for 120 minutes.
Rates of net transamination and decarboxylation of l-'4C-valine
were calculated based on the intracellular specific radioactivity
measured at the end of each incubation period [71. Intracellular
specific radioactivity measured at 60 minutes (618 17 DPM/
nmol valine) did not differ from that measured at 120 minutes
(644 29 DPM/nmol valine). Moreover, the rates of decarboxy-
lation at one hour were not statistically different (15.4 1.9, 1
hr, vs. 18.1 2.8 nmol/glhr, 2hr), making it likely that the
specific radioactivity of the a-ketoacid was nearly constant.
There was a 16% decrease (P = NS) in net transamination in the
second hour. This may mean that the intracellular BCAA
specific radioactivity achieves equilibrium earlier than did its
s-ketoacid, and to that extent, our method slightly overesti-
mates net transamination.
Immediately after the medium was removed from the flasks,
muscles were removed, washed in iced saline, blotted and
homogenized in 1.5 ml 5% PCA. The protein precipitate was
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Table 1. Weights, arterial blood acid-base and urea nitr
chronically uremic and control rats
ogen in
Groups
Weight g HCO3
Initial Final pH mrt
PUN
mg/dl
Experiment I
CRF
SO
140 4 183 7 7.27 002b 19 1130 r 182 5 7.37 0.01 24 1 120 6b31 2
Experiment 2
CRF-HCO3
SO-HCO3
130 3 195 4 7.42 0.01 24 1145 2 190 3 7.42 0.01 25 2 106 6'30± 1
Values are mean SaM from at least 18 rats in each group.
Abbreviations are: CRF, chronic renal failure; SO, sham-operated;
CRF-HCO3 and SO-HCO3, chronic renal failure and sham-operated
rats receiving supplemental bicarbonate; SUN, serum urea nitrogen;
HCO3, calculated blood bicarbonate
a p < 0.05
b P < 0.01 compared with SO group
washed with 3 ml iced 5% PCA, followed by two washes with 5
ml ethanol/ether (1:1, vollvol) and then solubilized by incubat-
ing overnight at 37°C in 0.5 ml Soluene 100 (United Technolo-
gies Packard, Downers Grove, Illinois, USA). Radioactivity
was determined by liquid scintillation counting with correction
for quenching using an external standard and a quench curve
generated using skeletal muscle protein; counting was per-
formed within 48 hours. The rate of amino acid incorporation
into protein was calculated from radioactivity in protein, di-
vided by the intracellular specific radioactivity of the amino
acid [11, 141.
Materials
L-[1-'4C]valine was purchased from New England Nuclear
(Boston, Massachusetts, USA) and L-[1-"C]leucine from ICN
(Irvine California, USA). Fatty acid and globulin-free albumin
and mercaptoethanol were purchased from Sigma (St. Louis,
Missouri, USA), tetrahydrofuran, o-phthaldialdehyde and HPLC
amino acid standards from Pierce Chemical Company (Rockford,
Illinois, USA) and HPLC grade methanol and water from
Fisher Scientific Company (Pittsburgh, Pennsylvania, USA).
Porcine insulin was purchased from Eli Lilly & Company
(Indianapolis, Indiana, USA).
Statistics
Results are presented as mean SEM and values for each
experiment were compared using Student's paired t-tests be-
cause the uremic and control rats were pair-fed and muscles
from each pair were studied simultaneously. Results were
considered significant at P < 0.05.
Results
One week following the right nephrectomy, we paired the rats
as closely as possible according to weight. Although there was
a small (P < 0.05) difference between the average weights of the
CRF versus SO and CRF-HCO3 versus SO-HCO3 groups at this
time, there was no difference in weights after the two-week
pair-feeding period (Table 1). The blood pH and bicarbonate
concentration and the PUN of CRF rats were significantly
different from those of SO rats (Table 1). The bicarbonate
concentration calculated from the blood pH and pCO2 mea-
sured at the time of the experiment revealed that all CRF rats
had a value <21 mEq/liter; the average value was 19 1
mEq/liter. Bicarbonate supplementation did not significantly
change the PUN of CRF rats, but corrected the metabolic
acidosis of CRF; it did not change the pH, blood bicarbonate or
PUN of SO rats (Table 1),
BCAA concentrations in plasma and the intracellular fluid of
muscle are presented in Table 2. Plasma BCAA levels were 12
to 18% lower in CRF rats compared to their pair-fed controls,
but these differences were not statistically significant. In mus-
cles from CRF rats, intracellular valine was significantly re-
duced while leucine and isoleucine were unaffected (experiment
1, Table 2). The difference between CRF and SO rats suggests
that the pools of valine, were decreased in uremic rats despite
a protein intake identical to that of the appropriate control rat.
In the second pair-feeding experiment (experiment 2), the
BCAA levels in both plasma and muscle of CRF-HCO3 rats
were higher than in their pair-fed controls, suggesting that
BCAA pools were higher. In both experiments, the intracellular
valine concentration exceeded the plasma level, as has been
reported by others in studies of non-uremic, fed rats [15]. The
intra- to extracellular ratios of BCAA we found were similar to
those reported [15] and did not differ significantly between
uremic and control rats in either experiment (Table 2). The high
plasma BCAA concentrations compared to previous studies of
amino acid levels in CRF rats [16, 17] reflect the fact that
samples in the present study were obtained from fed rats eating
a high-protein diet [181. We have no explanation for the finding
that the valine level in muscle of SO-HCO3 rats was lower than
that of SO rats. However, it is inadvisable to make comparisons
between groups of rats in experiments 1 and 2 because each
experiment was designed as a separate pair-feeding study, and
the pattern of daily food intake varied in each experiment.
BCAA decarboxylation rates by incubated epitrochlearis
muscles are presented in Figures 1 and 2. Valine decarboxyla-
tion was threefold greater in muscles from CRF compared to
control rats, both in the presence and absence of insulin (Fig.
1). The higher valine decarboxylation rate cannot be attributed
to an indirect stimulation of BCKAD activity by increased
intracellular leucine in uremic rats [6, 19], since intracellular
levels of this amino acid measured before (Table 2) or at the end
of the incubation period (Table 3) did not vary between the
groups. In contrast, when acidosis, but not uremia (Table 1),
was prevented by giving uremic rats NaHCO3, valine decar-
boxylation was actually one-third lower than in muscles of
control rats receiving the same amount of NaHCO3, though this
difference was not statistically significant (Figs. 1 and 2).
Leucine decarboxylation also was increased in muscles of
CRF compared to control rats (experiment 1), both in the
presence and absence of insulin (Fig. 2). As reported previ-
ously, leucine decarboxylation rates exceeded the rates for
valine [6, 7, 12, 20]. This is probably due to an increase in the
activity state of BCKAD associated with the higher intracellular
leucine levels (Table 3) caused by incubating with leucine [9, 21,
22]. On the other hand, differences in intracellular leucine
measured before the experiment or at the end of the incubation
(Tables 2, 3) cannot explain the higher rate occurring in CRF
compared to control muscles (Table 2). As with the valine
decarboxylation measurements, when the metabolic acidosis of
uremia was corrected (CRF-HCO3), leucine decarboxylation
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Fig. 1. Va/me decarboxylation rates in incubated epitrochlearis mus-
cles. Values represent mean SEM of muscles from at least 8 rats in
each group incubated with 0.2 mat valine. (A). Insulin was omitted from
the media. (B). The media was supplemented with 0.2% albumin and I
mU/mi insulin. Open bars represent values from CRF rats and solid
bars for their sham-operated, control rats in Experiment I. Striped and
dotted bars represent values from NaHCO3-treated CRF and control
rats, respectively in Experiment 2. * P < 0.05 compared to control.
was slightly lower than in control (SO-HCO3) muscles. Leu-
cine, like valine, decarboxylation was lower in the presence of
insulin (Figs. 1, 2).
We confirmed (Table 4) that the rate of net BCAA trans-
amination exceeds decarboxylation in skeletal muscle [5, 6, 7,
13, 19, 23] but, as noted (Methods) our measure of net trans-
amination probably overestimates the in vivo rate. Net trans-
amination rates for leucine or valine tended to be higher in CRF
muscles compared to control, but the differences were not
statistically significant. The net leucine transamination rate
exceeded that of valine, perhaps because the Km for leucine of
branched-chain, amino acid transaminase is lower than that for
valine [6]. It is unclear why insulin had different effects on
valine and leucine transamination. Since net transamination
was measured as the sum of decarboxylation and a-ketoacid
formation, a possible explanation is that insulin caused a greater
decrease in leucine compared to valine decarboxylation (Figs.
1, 2).
In experiment 1, the rates of valine and leucine incorporation
into protein in the absence of insulin were lower in muscles of
Table 3. Intracellular leucine concentrations in incubated muscles
Groups
Study A p Study B M
Basal + Insulin Basal + Insulin
Experiment I
CRF
SO
136 19 150 14
102 17 158 24
197 17 210 25
218 22 245 15
Experiment 2
CRF-HCO3
SO-HCO3
114 14 156 7
133 10 154 13
247 12 265 26
185 4 240 12
Values are man 5EM of muscles from at least 6 rats in each group.
In Study A, valine decarboxylation was measured during a two hour
incubation with 0.2 mat valine and L-[l-'4C]valine (0.25 mCi/mmoO.
Subsequently, the intracellular leucine was determined. In Study B,
leucine decarboxylation was measured by incubating with 0.15 mai
leucine and L-[l-'4C]leucine (0.33 mCi/mmol)
CRF compared to control rats; this was eliminated by feeding
NaHCO3 in experiment 2. Incorporation of valine and leucine
into protein was stimulated (P < 0.05) by insulin in muscles of
all groups (Table 5). However, in muscles of individual rats, the
increment in valine incorporation induced by insulin was less by
paired analysis (P < 0.05) in both uremic groups compared to
their respective controls. The same was true for leucine incor-
poration in muscles from CRF compared to SO rats. Although
the rate of leucine incorporation exceeded that of valine, this
may not represent a stimulation of protein synthesis by leucine
[24, 25] because there is more leucine than valine in skeletal
muscle protein [26].
Discussion
In this study, we found that the intracellular valine level in
muscle is depressed (Table 2) in rats with chronic uremia and a
blood bicarbonate concentration <21 mEq/liter. In this respect,
the model we studied reflects findings present in CRF patients
[1]. Plasma BCAA levels tended to be lower in CRF rats, but
the differences were not statistically significant. Since the lower
intracellular valine concentration was not associated with an
abnormal intra- to extracellular concentration gradient, the data
suggest that the valine pool is low in CRF if it can be assumed
that the distribution volume is unchanged. The lower intracel-
lular valine concentration cannot be attributedto a difference in
protein and hence valine intake, since the rats were pair-fed.
Nor can the difference be attributed to uremia, per Se, since
Experiment
CRF
SO
Table 2. In vivo concentrations of branched-chain amino acids in muscle and plasma
Muscle M Plasma p.
Valine Isoleucine Leucine Valine Isoleucine Leucine
689 34(180) 161 10(0.98) 306 10(0.85) 389 19 166 6 363 19
782 29(1.82) 166 23(0.86) 298 49(0.69) 440 35 203 24 430 30
Experiment 2
CRF-HCO3 741 52a(1.41) 249 19a(l.21) 414 55a(1.00) 539 58 218 30 460 70
SO-HCO3 518 30(1.38) 195 6(1.28) 286 22(0.90) 395 40 166 23 334±47
Values are mean SEM from 5 rats in each group. Numbers in parentheses indicate the ratio of the intra- to extracellular (plasma) concentration
of each branched-chain amino acid. Abbreviations are: CRF, chronic renal failure; SO, sham-operated control; CRF-HCO3 and SO-HCO3 are rats
receiving 1.7% dietary sodium bicarbonate
° P < 0.05 compared to sham-operated control
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FIg. 2. Leucine decarboxylation rates in incubated epitrochlearis mus-
cles. Values represent mean SEM of muscles from at least 6 rats in
each group incubated with 0.15 mat leucine. (A). Insulin was omitted
from the media. (B). The media was supplemented with 0.2% albumin
and 1 mU/ml insulin. Open bars represent values from CRF rats and
solid bars for their sham-operated, control rats in Experiment 1. Striped
and dotted bars represent values from NaHCO3-treated CRF and
control rats, respectively in Experiment 2. * P C 0.05 compared to
control.
intracellular valine in muscles of CRF-HCO3 rats actually
higher than that of SO-HCO3 rats, even though the degree of
azotemia was the same in CRF and CRF-HCO3 rats (Table 1).
This suggests that the lowtr in vivo valine concentration in
muscle of CRF rats was caused by increased decarboxylation.
In fact, decarboxylation of valine and leucine was found to be
accelerated in muscles of acidotic CRF rats (Figs. 1, 2).
Accelerated decarboxylation was due to the chronic metabolic
acidosis of CRF, rather than azotemia, because decarboxyla-
tion rates in muscles from CRF-HCO3 rats were lower com-
pared to those in pair-fed SO-HCO3 rats. Although the decar-
boxylation rates in muscles of CRF-HCO3 rats were not statis-
tically lower compared to SO-HCO3 rats, this may be important
because basal decarboxylation was 16% and 34% lower for
leucine and valine, respectively, and the plasma and muscle
levels in CRF-HCO3 rats were higher. These results suggest
that azotemia by itself depresses BCAA decarboxylation. Al-
though insulin reduced the decarboxylation of both leucine and
valine in muscles from all groups, the stimulation of decarboxy-
lation by CRF in experiment 1 persisted (Figs. 1, 2). The
mechanism by which insulin reduced BCAA decarboxylation is
unknown. A similar observation was reported by Hutson et al in
studies of fed, normal rats; the authors suggested that insulin
decreased BCAA oxidation by inhibiting protein degradation
and/or stimulating protein synthesis, leading to a reduced
intracellular pool of branched-chain ketoacids available for
decarboxylation [151. Thus, the in vitro decarboxylation mea-
surements (Figs. 1, 2) are consistent with the in vivo BCAA
concentrations (Table 2), although one must be cautious in
inferring in vivo BCAA decarboxylation rates from in vitro
rates.
Previously, we found that in non-azotemic rats, chronic
Table 4. Rats of net transamination of valine and leucine in skeletal
muscle
Groups
Valine
nMol/g/h
Leucine
nMol/g/h
Basal +Insulin Basal +Insulin
Experiment 1
CRF
SO
262±37 274±24
206±19 250÷19b
314±2Y 287±18
270±18 255±20
Experiment 2
CRF-HCO3
SO-HCO3
177 5 205 D
182 11 212 12b
268 20 225 18
313 15 253
Values are mean raM of muscles from at least 6 rats in each group.
Media contained 0.2 mat valine or 0.15 Mm leucine. In each experiment,
one muscle was incubated in media not containing insulin, and the
contralateral muscle incubated in media supplemented with 0.2%
albumin and 1 mU/ml insulin. Abbreviations are CRF, chronic renal
failure; SO, sham-operated; CRF-HCO3 and SO-HCO3, chronic renal
failure and sham-operated rats receiving supplemental sodium bicar-
bonate
a P < 0.05 compared with control
b P C 0.025 compared with basal conditions by paired i-test
Table S. Incorporation of valine or leucme into muscle protein
Valine Leucine
Groups
nMol/g/h nMol/g/h
Basal + Insulin Basal + Insulin
Experiment 1
CRF 65 6 110 loa.b 82 9 125
SO 84±7 1347b 108±7 16713b
Experiment 2
CRF-HCO3 88 2 126 4" 106 6 154 7"
SO-HCO3 79±5 l329" 105±9 1417b
Values are mean sEat of muscles from at least 6 rats in each group.
Media contained 0.2 mM valine or 0.15 m leucine. In each
experiment, one muscle was incubated in media not containing insulin,
and the contralateral muscle incubated in media supplemented with
0.2% albumin and 1 mU/ml insulin. Abbreviations are: CRF, chronic
renal failure; SO, sham-operated were 1.7%; CRF-HCO3 and SO-
HCO3, rats receiving sodium bicarbonate in the diet
a P < 0.05 compared with control
"P C 0.001 by paired i-test compared with basal
metabolic acidosis induced by feeding NH4C1 stimulates valine
and leucine decarboxylation by increasing both the total amount
of BCKAD in muscle and the percentage of BCKAD in the
active form [7]. In rats with CRF, the degree of acidosis was
less compared to this previous study, but the effect of acidosis
on BCAA metabolism was similar. Thus, we conclude that
oxidative decarboxylation of BCAA in muscle of CRF rats
(Figs. 1, 2) was stimulated by the same mechanism as in
acidotic, non-azotemic rats. Decarboxylation was returned to
normal when acidosis, but not azotemia (Table 1), was cor-
rected. Because the rat has a high capacity to excrete acid, it
was necessary to feed the CRF rats a high-protein diet in order
to induce moderate azotemia and a mild metabolic acidosis.
Previous studies of rats have not shown that CRF causes
decreased BCAA levels [16, 17]. In these reports, rats were fed
lower amounts of protein, and this plus their capacity for acid
excretion may have prevented metabolic acidosis. Unfortu-
nately, the acid-base status of rats in these previous studies [16,
210
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171 was not reported. Although dietary protein clearly affects
BCAA levels [8], the pair-feeding comparisons we used allowed
us to isolate an important, independent effect of metabolic
acidosis on BCAA metabolism.
Potential mechanisms for the stimulation of BCKAD include
increased intracellular a-ketoisocaproate and/or increased glu-
cocorticoid production [6, 19, 21, 27]. Although the intracellular
a-ketoisocaproate concentration could not be accurately mea-
sured, both intracellular leucine and the net rate of its trans-
amination were virtually the same in muscles of CRF or SO rats
(Tables 2, 3). It seems unlikely, therefore, that a-ketoisocapr-
oate caused the differences in BCAA decarboxylation we
observed. A second mechanism for the increased BCAA decar-
boxylation in CRF might involve glucocorticoids since pharma-
cologic doses increase skeletal muscle BCKAD activity in
normal rats [28] and in rats, glucocorticoid production is
increased by acidosis [291. It is unlikely that this is the sole
mechanism, however, since we also have found that corticos-
terone excretion is increased in rats with CRF, even when their
acidosis is corrected by supplemental bicarbonate [9]. Since
BCAA decarboxylation is not stimulated when muscles from
normal rats are incubated in acidified media [7], and since all
muscles in the present study were incubated at pH 7.4, it
appears that the acidosis must be chronic to cause a change in
BCAA decarboxylation. Perhaps, both metabolic acidosis and
increased glucocorticoid production are required to stimulate
BCAA decarboxylation in CRF rats. This would be interesting
because this combination accelerates protein degradation in
muscle of non-uremic rats [29].
A lower plasma and intracellular concentration of BCAA
(and especially valine) in uremic humans implies that the pools
of BCAA are depressed in uremia [1]. Smaller pools cannot be
explained adequately by differences in protein intake [2] nor is
there direct evidence for selective malabsorption of BCAA [3].
This leads to the conclusion that there is increased utilization of
BCAA by peripheral tissues, principally liver and skeletal
muscle. Although BCAA could be transaminated in peripheral
tissues, with the resulting a-ketoacids decarboxylated in the
liver, it seems unlikely that this is the major cause of low BCAA
pools since plasma levels of branched-chain a-ketoacids are low
in CRF patients [30, 31]. Moreover, splanchnic catabolism of
branched-chain a-ketoacids must be reduced in uremia since
oral administration of a-ketoisovalerate leads to a higher plasma
level in CRF patients compared to normal subjects [32], and
orally administered a-ketoisocaproate is incorporated into non-
splanchnic protein with greater efficiency in uremic compared
to control rats [33]. From the present data (Table 5) and our
previous measurements of muscle protein synthesis in CRF, it
seem unlikely that an increase in BCAA incorporation into
muscle protein can account for the low BCAA pools in uremia.
This leaves excessive catabolism of BCAA by muscle as the
most likely explanation for the reduced BCAA pools in CRF.
There are reports suggesting that BCAA catabolism is not
increased by CRF. Jones and Kopple infused 1-'4C-valine into
five control and three uremic subjects eating a high-carbohy-
drate, low-protein diet and measured the rate of expired '4C02
after an overnight fast [2]. Valine decarboxylation was calcu-
lated using the plasma amino acid, specific radioactivity, and it
was concluded that the rate of inrreversible loss of valine was
reduced 28% in the uremic subjects. Recently, the accuracy of
this calculation has been questioned [12], since there are
important differences between the plasma amino acid and
intracellular a-ketoacid (the precursor pool for decarboxylation)
specific radioactivities. Fortunately, the intracellular BCAA spe-
cific radioactivity (which we used) and that of the respective
a-ketoacid are equal in muscle [12]. Epstein et al compared the
'4C02 excretion rates of two uremic and two control subjects
eating diets containing S g of protein plus an amino acid
supplement in which a-ketoisovalerate was substituted for
valine [34]. The decarboxylation of an oral load of [1-'4C]a-
ketoisovalerate was calculated from the expired '4C02 and its
specific radioactivity, and it was concluded that uremic and
normal subjects did not differ [34]. Unfortunately, the acid-base
status of patients in both of these studies was not presented.
Thus, it is not clear that the present results can be extrapolated
to humans.
Certain observations suggest that in muscle, BCAA metabo-
lism and protein catabolism share common control mecha-
nisms. In rats, both streptozotocin-induced diabetic ketoacido-
sis and NH4C1-induced acidosis are associated with increased
protein catabolism and BCAA decarboxylation in skeletal mus-
cle [7, 20, 29]. In CRF, nitrogen balance in humans [35] and
nitrogen excretion in rats [9] is improved by administering
sufficient NaHCO3 to correct the acidosis. The design of the
present experiments did not permit an examination of the
effects of bicarbonate supplementation on nitrogen utilization in
CRF rats. The average daily ratio of weight gain per gram of
food of the CRF-HCO3 group was significantly (P < 0.01)
greater than that of the CRF group (0.53 0.01, CRF-HCO3 vs.
0.30 0.04, CRF). It also was greater than that of the pair-fed
SO-HCO3 group (0.53 0.01, CRF-HCO3 vs. 0.39 0.02,
SO-HCO3; P < 0.01). Although these data suggest that bicar-
bonate supplementation improved dietary protein utilization,
we believe this conclusion is unwarranted because there was no
difference in this ratio between SO and SO-HCO3 rats (0.37
0.02, 50 vs. 0.39 0.02, SO-HCO3). Furthermore, we have
measured nitrogen intake and excretion in another study de-
signed to assess the effects of metabolic acidosis on muscle
protein metabolism in rats with CRF [9]. In that study, there
was no significant difference in nitrogen balance between CRF-
HCO3 and pair-fed SO-HCO3 rats. An alternative explanation
for the greater weight gain of CRF-HCO3 rats would be linked
to their higher sodium intake (—S 4.5 mEq Na/day) compared to
the CRF group (— 1.7 mEq Na/day).
Our finding that in CRF, excessive BCAA catabolism and
protein degradation in muscle are corrected by NaHCO3,
suggests that protein and BCAA catabolism in muscle are
linked. It is tempting to ascribe the accelerated muscle prote-
olysis of CRF to excessive leucine catabolism because leucine
can stimulate muscle protein synthesis in vitro [24, 25] and its
c-ketoacid, a-ketoisocaproate, reduces muscle proteolysis in
vitro [25] and nitrogen excretion in vivo [36]. Alternatively,
BCAA catabolism and muscle protein breakdown may be a
coordinated response to acidosis and other catabolic condi-
tions.
Low protein diets supplemented with essential amino acids or
a-ketoacids are being used increasingly in the conservative
treatment of uremic patients. It also has been suggested that
BCAA can be useful in treating patients with catabolic condi-
tions [37]. For this reason, it is important to identify factors
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which might lower the efficiency by which BCAA or their
a-ketoacids are utilized. One factor is chronic metabolic acido-
sis. It should be emphasized that in the present study, the
degree of acidosis causing excessive BCAA catabolism was not
severe (average bicarbonate, 19 1 mEq/liter). Correction of
acidosis should be a goal of therapy, especially when treatment
consists of limiting quantities of BCAA or branched-chain
ketoacids given with low protein diets.
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